GlassScriptPhysician profile
Derick Petrie
NPI 1538559927
$3,594.35
in general payments reported to CMS, 2019-2025
34 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $739 · 2023: $816 · 2024: $811 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.83 | 2021-2025 | |
| Novo Nordisk INC | $414.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $410.97 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $370.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $239.14 | 2021-2024 | Nexletol |
| Glaxosmithkline, LLC. | $189.14 | 2023-2025 | Trelegy Ellipta |
| Tolmar, INC. | $169.28 | 2023-2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.06 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.82 | 2021-2025 | Xifaxan, Trulance |
| Corium, LLC | $111.83 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.21 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $64.93 | 2022-2025 | Auvelity, Symbravo |
| Acerus Pharmaceuticals Corporation | $57.07 | 2021-2022 | |
| Abbott Laboratories | $56.04 | 2021-2025 | Freestyle Libre |
| Biohaven Pharmaceuticals, INC. | $47.05 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.73 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $28.27 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.56 | 2025 | Voquezna |
| Exact Sciences Corporation | $23.13 | 2025 | The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $20.32 | 2025 | Alvesco |
| Kowa Pharmaceuticals America, INC. | $20.01 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $19.43 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.08 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.05 | 2023 | Quviviq |
| Clarus Therapeutics INC. | $16.78 | 2021 | |
| Amgen INC. | $16.33 | 2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $15.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.02 | 2022 | |
| Amarin Pharma, INC. | $14.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.07 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.92 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $13.62 | 2021 | |
| Genentech USA, INC. | $4.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derick Petrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.